N,N-dimethyl-n-octadecylamine borane 1¯
at 8 mg/kg/day, tetrakis-u-(trimethylamine
boranecarboxylato)-bis(trimethyl-carboxyborane)-dicopper(II) 2¯
at 2.5 mg/kg/day and
trimethylamine-carboxyborane 3¯
at 8 mg/kg/day were evaluated for their effects on bile lipids, bile
acids, small intestinal absorption of cholesterol and cholic acid and liver and small intestinal
enzyme activities involved in lipid metabolism. The agent administered orally elevated rat bile
excretion of lipids, e.g. cholesterol and phospholipids, and compounds 2¯ and 3¯ increased the bile
flow rate. These agents altered the composition of the bile acids, but there was no significant
increase in lithocholic acid which is most lithogenic agent in rats. The three agents did decrease
cholesterol absorption from isolated in situ intestinal duodenum loops in the presence of drug.
Hepatic and small intestinal mucosa enzyme activities, e.g. ATP-dependent citrate lyase, acyl
CoA cholesterol acyl transferase, cholsterol-7-α
-hydroxylase, sn glycerol-3-phosphate acyl
transferase, phosphatidylate phosphohydrolase, and lipoprotein lipase, were reduced. However,
the boron derivatives 1¯ and 3¯ decreased hepatic HMG-CoA reductase activity, the regulatory
enzyme for cholesterol synthesis, but the compounds had no effects on small intestinal mucosa
HMG-CoA reductase activity. There was no evidence of hepatic cell damage afforded by the
drugs based on clinical chemistry values which would induce alterations in bile acid concentrations
after treatment of the rat.